Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5658824 | 0.95 | NPC1 (0.41) | POLBNPSR1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL134199 | 0.82 | TDP1 (0.55) | MEN1KMT2ASMN1; SMN2TSHRCYP1A2 | |
| SCHEMBL28000445 | 0.78 | HTR2A (0.61) | CYP1A2 | |
| SCHEMBL14938621 | 0.77 | SMN1; SMN2 (0.44) | POLBNPSR1BRD4SMN1; SMN2NPC1 | |
| SCHEMBL1197416 | 0.77 | NPC1 (0.46) | KMT2ASMN1; SMN2NPC1RAB9AKDM4E | |
| SCHEMBL14938619 | 0.77 | BRD4 (0.47) | POLBNPSR1BRD4MEN1KMT2A | |
| SCHEMBL11399267 | 0.76 | ALDH1A1 (0.60) | POLBNPSR1BRD4SMN1; SMN2NPC1 | |
| SCHEMBL2700735 | 0.76 | TDP1 (0.65) | MEN1KMT2ASMN1; SMN2NPC1RAB9A | |
| SCHEMBL4780152 | 0.76 | HTR2C (0.42) | — | |
| SCHEMBL4726241 | 0.76 | MCHR1 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008012622-A2 | AZABENZIMIDAZOLYL COMPOUNDS AS POTENTIATORS OF MGLUR2 SUBTYPE OF GLUTAMATE RECEPTOR | PFIZER PRODUCTS INC. (US) | 2008-01-31 | — | — | WO | claimed |
| EP-0193227-A1 | Process for the preparation of arylglycidyl ethers and 3-substituted 1-alkylamino-2-propanols | GIST-BROCADES N.V. (NL) | 1986-09-03 | — | — | EP | claimed |
| US-9631048-B2 | Sulfonium compounds, their preparation and use | BASF SE (DE) | 2017-04-25 | — | — | US | disclosed |
| CN-104379628-B | Sulfonium compound, it prepares and application thereof | 巴斯夫欧洲公司 | 2016-11-16 | — | — | CN | disclosed |
| EP-2791121-B1 | BENZISOTHIAZOL-3(1H)-ONE-5-SULFONYL DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN INC (US) | 2016-08-03 | — | — | EP | disclosed |
| EP-2838927-A2 | SULFONIUM COMPOUNDS, THEIR PREPARATION AND USE | BASF SE (DE) | 2015-02-25 | — | — | EP | disclosed |
| US-20150044509-A1 | SULFONIUM COMPOUNDS, THEIR PREPARATION AND USE | BASF SE (DE) | 2015-02-12 | — | — | US | disclosed |
| US-20140005301-A1 | SULFONIUM SULFATES, THEIR PREPARATION AND USE | BASF SE (DE) | 2014-01-02 | — | — | US | disclosed |
| EP-2678311-A1 | SULFONIUM SULFATES, THEIR PREPARATION AND USE | BASF SE (DE) | 2014-01-01 | — | — | EP | disclosed |
| US-8586268-B2 | Oxime ester photoinitiators | BASF SE (DE) | 2013-11-19 | — | — | US | disclosed |
| WO-2013156509-A2 | SULFONIUM COMPOUNDS, THEIR PREPARATION AND USE | BASF SE (DE) | 2013-10-24 | — | — | WO | disclosed |
| EP-0229947-B1 | NOVEL CRYSTALLINE SALTS OF ARYLOXY-PROPANOLAMINES, THEIR PREPARATION AND THEIR USE | RORER INTERNATIONAL (OVERSEAS) INC. (US) | 1991-03-13 | — | — | EP | disclosed |
| US-4849530-A | Process for the preparation of crystalline salts or aryloxy-propanolamines | RORER PHARMACEUTICAL CORPORATION (US) | 1989-07-18 | — | — | US | disclosed |
| US-4767784-A | DIPHENYLACETATES | RORER PHARMACEUTICAL CORPORATION | 1988-08-30 | — | — | US | disclosed |
| EP-0229947-A1 | Novel crystalline salts of aryloxy-propanolamines, their preparation and their use | RORER INTERNATIONAL (OVERSEAS) INC. (US) | 1987-07-29 | — | — | EP | disclosed |
| US-4391980-A | FOR INVERSION OF CONFIGURATION OF OPTICALLY ACTIVE COMPOUNDS | CIBA-GEIGY CORPORATION (US) | 1983-07-05 | — | — | US | disclosed |
| EP-0007605-B1 | A PROCESS FOR INVERTING THE CONFIGURATION IN OPTICALLY ACTIVE COMPOUNDS AND OPTICALLY ACTIVE INTERMEDIATE COMPOUNDS AND THEIR SALTS REQUIRED THEREFOR | CIBA-GEIGY AG (CH) | 1982-09-15 | — | — | EP | disclosed |
| US-4294966-A | SALT FORMATION | CIBA-GEIGY CORPORATION (US) | 1981-10-13 | — | — | US | disclosed |
| EP-0007605-A1 | A process for inverting the configuration in optically active compounds and optically active intermediate compounds and their salts required therefor | CIBA-GEIGY AG (CH) | 1980-02-06 | — | — | EP | disclosed |
| US-4182911-A | BETA-ADRENERGIC BLOCKING AGENTS | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1980-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150044509-A1 | SULFONIUM COMPOUNDS, THEIR PREPARATION AND USE | SQOR, ACSL3, ARSA | POLB 2497/4885NPSR1 1138/4885BRD4 1161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.